This is a phase II randomized controlled study of miglustat in adult and juvenile patients
with Niemann-Pick Type C disease. Up to 42 patients will be randomised in a 2:1 ratio to
either treatment with miglustat or to a non-treatment group. Both groups will follow an
identical visit schedule.